Table 7. Effectiveness of montelukast compared with placebo in the high ECP group (ECP ≥15 µg/L).

	Changes after taking Montelukast (Mean±SD)	Changes after taking Placebo drug (Mean±SD)	P value
SCORAD index	-2.2±10.5	-7.8±11.2	0.21
Urine LTE4 (pg/mL)	-8.8± 557.9	146.8±487.0	0.44
Urine EDN (ng/mL)	-356.0±857.7	-229.6±1,029.3	0.81

ECP, eosinophil cationic protein; SCORAD, SCORing Atopic Dermatitis; LTE₄, leukotriene E₄; EDN, eosinophil-derived neurotoxin.